Last $80.18 USD
Change Today +1.31 / 1.66%
Volume 1.9M
ENDP On Other Exchanges
As of 2:01 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

endo international plc (ENDP) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/4/14 - $82.16
52 Week Low
04/15/14 - $53.62
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

endo international plc (ENDP) Details

Endo International plc, a specialty healthcare company, develops, manufactures, markets, and distributes branded pharmaceutical and generic products, and medical devices worldwide. It provides branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar, and Fortesta Gel to treat and manage pain and conditions in urology, endocrinology, and oncology. The company also offers non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health, and hypertension markets; and pharmaceutical products in the areas of ADHD, pain, urology, and allergy. In addition, it provides various medical devices comprising AMS 700 MS series, AMS 800 artificial urinary sphincters, GreenLight XPS laser systems, Elevate anterior and posterior pelvic floor repair systems, and Monarc subfascial hammock products in the areas of men’s and women’s health, and prostate health. The company’s products also include Aveed, an injectable testosterone preparation to treat male hypogonadism; and BEMA Buprenorphine, a transmucosal form of buprenorphine in Phase III trials for treating moderate to severe chronic pain. It serves pharmacy chains directly; and hospitals, governmental agencies, pharmacies, and physicians through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

3,371 Employees
Last Reported Date: 03/3/14
Founded in 1920

endo international plc (ENDP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $4.3M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $157.0K
Chief Legal Officer, Executive Vice President...
Total Annual Compensation: $562.0K
Chief Operating Officer of Pharmaceuticals
Total Annual Compensation: $270.8K
Compensation as of Fiscal Year 2013.

endo international plc (ENDP) Key Developments

Endo International plc Announces Management Changes, Effective March 1, 2015

Endo International plc has announced changes to its executive leadership and senior management team. Under the new management structure, Endo's US branded pharmaceuticals and US generics business units, as well as the company's branded pharmaceutical R&D will report directly to Rajiv De Silva, president and CEO of Endo. Mr. DeGolyer will step down effective March 1, 2015 and remain with the company until August 1, 2015 in the capacity of a special advisor to the CEO.

Endo International plc Announces Executive Changes

Endo International plc announced management changes. Don DeGolyer, Chief Operating Officer, Pharmaceuticals has decided to leave Endo International plc to pursue other opportunities. Mr. DeGolyer will step down effective March 1, 2015 and remain with the company until August 1, 2015 in the capacity of a special advisor to the CEO. Blaine Davis will become the Senior Vice President and General Manager of the newly created specialty pharmaceuticals business unit, reporting to Mr. Lortie. Mr. Davis had previously been President of Endo Ventures Limited and Senior Vice President of Corporate Affairs. Keri Mattox, Auxilium's current Senior Vice President of Investor Relations and Corporate Communications, will serve as Senior Vice President of Investor Relations and Corporate Affairs reporting to Suky Upadhyay, Endo's EVP and Chief Financial Officer. Ms. Mattox brings more than 15 years of experience in strategic life sciences communications, investor relations and journalism to Endo.

Endo International plc Announces Retirement of Caroline B. Manogue as Executive Vice President, Chief Legal Officer Effective July 1, 2015

Endo International plc announced that Caroline B. Manogue, Executive Vice President, Chief Legal Officer has advised the company that she intends to retire from the company on July 1, 2015. Endo has retained a leading executive search firm to assist in identifying a successor. Ms. Manogue will continue to serve in her role during the search process and through a transition period once her successor has been named.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENDP:US $80.23 USD +1.36

ENDP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $178.63 USD +0.43
Dr Reddy's Laboratories Ltd 3,350 INR -11.65
Edwards Lifesciences Corp $129.97 USD +0.34
Hologic Inc $29.50 USD +0.155
Mallinckrodt PLC $107.06 USD +0.08
View Industry Companies

Industry Analysis


Industry Average

Valuation ENDP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.5x
Price/Book 4.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDO INTERNATIONAL PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at